MaxCyte outlines $30M-$32M 2026 revenue outlook as board authorizes $10M share repurchase program
Source: SeekingAlpha
2026-05-13 02:02:18 ET
More on MaxCyte
- MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
- MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript
- MaxCyte GAAP EPS of -$0.04 beats by $0.04, revenue of $9.7M beats by $2.4M
- MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook
- Seeking Alpha’s Quant Rating on MaxCyte
Read the full article on Seeking Alpha
For further details see:
MaxCyte outlines $30M-$32M 2026 revenue outlook as board authorizes $10M share repurchase program
MaxCyte Inc.
NASDAQ: MXCT
MXCT Trading
5.77% G/L:
$1.10 Last:
851,200 Volume:
$1.04 Open:
MXCT Latest News
May 12, 2026 04:05:00 pm
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MXCT Stock Data
$82,138,988
103,153,769
1.05%
195
N/A
Biotechnology & Life Sciences
Healthcare
US
Rockville
